Health Care Utilization and Costs of Patients With Prostate Cancer in China Based on National Health Insurance Database From 2015 to 2017

Overview

Journal Front Pharmacol

Date 2020 Jun 27

PMID 32587512

Citations 13

Authors

Lin Bai

Haishaerjiang Wushouer

Cong Huang

Zhenhuan Luo

Xiaodong Guan

Luwen Shi

Affiliations

Soon will be listed here.

Abstract

Background: In terms of medical costs, prostate cancer is on the increase as one of the most costly cancers, posing a tremendous economic burden, but evidence on the health care utilization and medical expenditure of prostate cancer has been absent in China.

Objective: This study aimed to analyze health care utilization and direct medical costs of patients with prostate cancer in China.

Methods: Health care service data with a national representative sample of basic medical insurance beneficiaries between 2015 and 2017 were obtained from the China Health Insurance Association database. We conducted descriptive and statistical analyses of health care utilization, annual direct medical costs, and composition based on cancer-related medical records. Health care utilization was measured by the number of hospital visits and the length of stay.

Results: A total of 3,936 patients with prostate cancer and 24,686 cancer-related visits between 2015 and 2017 were identified in the database. The number of annual outpatient and inpatient visits per patient differed significantly from 2015 to 2017. There was no obvious change in length of stay and annual direct medical costs from 2015 to 2017. The number of annual visits per patient (outpatient: 3.0 vs. 4.0, P < 0.01; inpatient: 1.5 vs. 2.0, P < 0.001) and the annual medical direct costs per patient (US$2,300.1 vs. US$3,543.3, P < 0.001) of patients covered by the Urban Rural Resident Basic Medical Insurance (URRBMI) were both lower than those of patients covered by the Urban Employee Basic Medical Insurance (UEBMI), and the median out-of-pocket expense of URRBMI was higher than that of UEBMI (US$926.6 vs. US$594.0, P < 0.001). The annual direct medical costs of patients with prostate cancer in Western regions were significantly lower than those of patients in Eastern and Central regions (East: US$4011.9; Central: US$3458.6; West: US$2115.5) (P < 0.001).

Conclusions: There was an imbalanced distribution of health care utilization among regions in China. The direct medical costs of Chinese patients with prostate cancer remained stable, but the gap in health care utilization and medical costs between two different insurance schemes and among regions still needed to be further addressed.

Citing Articles

Provision of prostate cancer services in Tanzania: perspectives from five tertiary hospitals.

Nyongole O, Sirili N, Frumence G, Simba D, Urassa D, Sunguya B BMC Health Serv Res. 2024; 24(1):1154.

PMID: 39350208 PMC: 11443861. DOI: 10.1186/s12913-024-11580-1.

The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data.

Li B, Wang Y, Yi Y, Zhou N, Lv Z, Ma R BMC Public Health. 2024; 24(1):1309.

PMID: 38745323 PMC: 11092061. DOI: 10.1186/s12889-024-18820-3.

Potentially inappropriate medications among older patients with Parkinson's disease: a cross-sectional analysis of a national health insurance database in China.

Fu M, Li C, Zhao Z, Ling K, Gong Z, Li H BMC Geriatr. 2023; 23(1):827.

PMID: 38066430 PMC: 10709967. DOI: 10.1186/s12877-023-04547-0.

Cost Drivers and Financial Burden for Cancer-Affected Families in China: A Systematic Review.

Jia Y, Jiang W, Yang B, Tang S, Long Q Curr Oncol. 2023; 30(8):7654-7671.

PMID: 37623036 PMC: 10453571. DOI: 10.3390/curroncol30080555.

The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data.

Yang Y, Zhang Y, Wagner A, Li H, Shi L, Guan X J Glob Health. 2023; 13:04083.

PMID: 37566690 PMC: 10420358. DOI: 10.7189/jogh.13.04083.

References

Smith-Palmer J, Takizawa C, Valentine W . Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada. BMC Urol. 2019; 19(1):19. PMC: 6421711. DOI: 10.1186/s12894-019-0448-6. View

Yong M, Xianjun X, Jinghu L, Yunyun F . Effect of health insurance on direct hospitalisation costs for in-patients with ischaemic stroke in China. Aust Health Rev. 2017; 42(1):39-44. DOI: 10.1071/AH16056. View

Grover S, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M . The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. CMAJ. 2000; 162(7):987-92. PMC: 1232350. View

Liu G, Vortherms S, Hong X . China's Health Reform Update. Annu Rev Public Health. 2017; 38:431-448. DOI: 10.1146/annurev-publhealth-031816-044247. View

Satoh T, Ledesma D, Yoshihara N . The Economic Burden of Metastatic Castration Resistant Prostate Cancer and Skeletal Related Events in Japanese University Hospitals. Asian Pac J Cancer Prev. 2018; 19(1):21-26. PMC: 5844620. DOI: 10.22034/APJCP.2018.19.1.21. View

Zheng R, Sun K, Zhang S, Zeng H, Zou X, Chen R . [Report of cancer epidemiology in China, 2015]. Zhonghua Zhong Liu Za Zhi. 2019; 41(1):19-28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.005. View

Mervin M, Lowe A, Gardiner R, Smith D, Aitken J, Chambers S . What does it cost Medicare to diagnose and treat men with localized prostate cancer in the first year?. Asia Pac J Clin Oncol. 2017; 13(3):152-159. DOI: 10.1111/ajco.12663. View

Crawford E, Black L, Eaddy M, Kruep E . A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer. Prostate Cancer Prostatic Dis. 2010; 13(2):162-7. DOI: 10.1038/pcan.2009.63. View

Zhou M, Wang H, Zhu J, Chen W, Wang L, Liu S . Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 387(10015):251-72. DOI: 10.1016/S0140-6736(15)00551-6. View

10.

Sanyal C, Aprikian A, Chevalier S, Cury F, Dragomir A . Direct cost for initial management of prostate cancer: a systematic review. Curr Oncol. 2013; 20(6):e522-31. PMC: 3851348. DOI: 10.3747/co.20.1630. View

11.

Zong X, Zhang J, Ji X, Gao J, Ji J . Patterns of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting in China. Chin J Cancer Res. 2016; 28(2):168-79. PMC: 4865609. DOI: 10.21147/j.issn.1000-9604.2016.02.04. View

12.

Feng Y, Xiong X, Xue Q, Yao L, Luo F, Xiang L . The impact of medical insurance policies on the hospitalization services utilization of people with schizophrenia: A case study in Changsha, China. Pak J Med Sci. 2013; 29(3):793-8. PMC: 3809281. DOI: 10.12669/pjms.293.3273. View

13.

Zhang T, Xu Y, Ren J, Sun L, Liu C . Inequality in the distribution of health resources and health services in China: hospitals versus primary care institutions. Int J Equity Health. 2017; 16(1):42. PMC: 5335774. DOI: 10.1186/s12939-017-0543-9. View

14.

Yuan G, Liang L, Zhang Z, Liang Q, Huang Z, Zhang H . Hospitalization costs of treating colorectal cancer in China: A retrospective analysis. Medicine (Baltimore). 2019; 98(33):e16718. PMC: 6831262. DOI: 10.1097/MD.0000000000016718. View

15.

Kitazawa T, Matsumoto K, Fujita S, Seto K, Hanaoka S, Hasegawa T . Cost of illness of the prostate cancer in Japan--a time-trend analysis and future projections. BMC Health Serv Res. 2015; 15:453. PMC: 4593231. DOI: 10.1186/s12913-015-1103-x. View

16.

Fourcade R, Benedict A, Black L, Stokes M, Alcaraz A, Castro R . Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK. BJU Int. 2010; 105(1):49-56. DOI: 10.1111/j.1464-410X.2009.08716.x. View

17.

Grover S, Zowall H, Coupal L, Krahn M . Prostate cancer: 12. The economic burden. CMAJ. 1999; 160(5):685-90. PMC: 1230115. View

18.

Feng X, Pang M, Beard J . Health system strengthening and hypertension awareness, treatment and control: data from the China Health and Retirement Longitudinal Study. Bull World Health Organ. 2014; 92(1):29-41. PMC: 3865551. DOI: 10.2471/BLT.13.124495. View

19.

Meng Q, Fang H, Liu X, Yuan B, Xu J . Consolidating the social health insurance schemes in China: towards an equitable and efficient health system. Lancet. 2015; 386(10002):1484-92. DOI: 10.1016/S0140-6736(15)00342-6. View

20.

Felix J, Andreozzi V, Soares M, Borrego P, Gervasio H, Moreira A . Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System. Value Health. 2011; 14(4):499-505. DOI: 10.1016/j.jval.2010.11.014. View